Augmentin Dosing for Group B Streptococcus with eGFR 16 mL/min/1.73 m²
For a patient with eGFR 16 mL/min/1.73 m² requiring treatment of Group B Streptococcus infection, amoxicillin-clavulanate (Augmentin) is not the recommended first-line agent—penicillin G or ampicillin should be used instead—but if Augmentin must be used, dose 250-500 mg every 24 hours based on severity, as severe renal impairment dramatically reduces amoxicillin clearance while clavulanate clearance remains relatively preserved.
Critical Context: Augmentin is Not First-Line for GBS
The CDC guidelines for Group B Streptococcus clearly recommend penicillin G as the first-line agent (5 million units IV loading dose, then 2.5-3.0 million units IV every 4 hours), with ampicillin as an acceptable alternative 1. Augmentin (amoxicillin-clavulanate) is not mentioned in GBS treatment protocols because:
- The clavulanate component provides no benefit against GBS (which does not produce beta-lactamases)
- GBS remains universally susceptible to penicillin
- The fixed-ratio combination creates dosing challenges in renal failure
Pharmacokinetic Considerations in Severe Renal Impairment
If Augmentin must be used despite not being guideline-recommended, understanding the differential renal clearance is essential:
Amoxicillin clearance is profoundly affected by renal function, while clavulanate clearance is less dependent on GFR 2. In patients with eGFR 16 mL/min/1.73 m², research demonstrates:
- The amoxicillin-to-clavulanate AUC ratio increases from 4.9 (at normal GFR) to 13.4-14.7 in severe renal impairment 2
- Total body clearance of amoxicillin decreases dramatically with declining GFR 2
- Both renal and non-renal clearance pathways are affected 2
This means amoxicillin accumulates disproportionately compared to clavulanate in renal failure, creating risk of toxicity (particularly neurotoxicity with high doses) while the clavulanate component remains at relatively lower levels.
Dosing Algorithm for eGFR 16 mL/min/1.73 m²
Standard Renal Dosing Approach:
- For mild-moderate infections: 250 mg every 24 hours
- For severe infections: 500 mg every 24 hours (maximum)
- Avoid the 875 mg formulation entirely in this degree of renal impairment
Key Dosing Principles:
- Extend dosing interval to every 24 hours rather than reducing individual doses, as this maintains peak concentrations needed for bacterial killing while allowing clearance time
- Monitor for accumulation toxicity: confusion, seizures (amoxicillin neurotoxicity), particularly if doses exceed 500 mg/day
- Consider hemodialysis timing: If patient is on dialysis, give dose after dialysis session (both drugs are dialyzable) 2
Clinical Pitfalls and Caveats
Major Concerns:
- The clavulanate component serves no purpose for GBS and only adds unnecessary drug exposure and potential adverse effects
- Recent ICU data confirms that renal function is the primary determinant of beta-lactam exposure, not body weight 3—this eGFR of 16 represents severe impairment requiring aggressive dose reduction
- The fixed 4:1 ratio of amoxicillin:clavulanate in standard formulations becomes increasingly inappropriate as renal function declines 2
Monitoring Requirements:
- Watch for disproportionate amoxicillin accumulation manifesting as CNS toxicity
- The therapeutic target for amoxicillin against Streptococcus species is maintaining concentrations above MIC for 40-50% of the dosing interval—easily achieved even with reduced dosing given the low MIC of GBS to penicillins
- Avoid using eGFR cutoffs designed for normal dosing (like the 48 mL/min threshold identified for standard ICU dosing 4)—at eGFR 16, you are well into territory requiring maximum dose reduction
Strongly Recommended Alternative
Switch to penicillin G or ampicillin per CDC guidelines 1, which:
- Are the evidence-based first-line agents for GBS
- Have simpler renal dosing adjustments
- Avoid unnecessary clavulanate exposure
- Have decades of safety data in renal impairment
If penicillin allergy exists, the CDC recommends cefazolin (if not high-risk for anaphylaxis), clindamycin (if susceptible), or vancomycin 1—all preferable to Augmentin for this indication.